azacitidine has been researched along with Granuloma, Hodgkin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kewitz, S; Staege, MS | 1 |
| Kewitz, S; Kramm, CM; Staege, MS; Stiefel, M | 1 |
| Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
| Bacigalupo, A; Bregante, S; Colombo, N; Di Grazia, C; Dominietto, A; Galaverna, F; Geroldi, S; Ghiso, A; Grasso, R; Gualandi, F; Lamparelli, T; Luchetti, S; Raiola, AM; Stasia, A; Van Lint, MT; Varaldo, R | 1 |
| Beyá, MD; Cordeiro, A; Díaz, T; Ferrer, G; Fuster, D; Martinez, A; Monzó, M; Navarro, A | 1 |
| Amengual, JE; Colbourn, DS; Deng, C; Falchi, L; Khan, KA; Lichtenstein, EA; O'Connor, OA; Sawas, A; Schwartz, LH | 1 |
| Chua, N; Saini, L | 1 |
| Swerev, TM; Ushmorov, A; Wirth, T | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Bozzoli, V; Calcagni, ML; D'Alò, F; Hohaus, S; Leone, G; Rufini, V; Teofili, L; Tisi, MC; Voso, MT | 1 |
| Bollard, CM; Copeland, A; Cruz, CR; Gerdemann, U; Heslop, HE; Horton, TM; Ku, S; Leen, AM; Rooney, CM; Shafer, JA; Sheehan, A; Tzou, B; Younes, A | 1 |
| Rezvani, K | 1 |
| Fujimoto, H; Imamura, M; Kato, N; Kondo, T; Matsumura, N; Minami, Y; Oishi, I; Tanaka, Y; Tsukada, J; Yoda, A | 1 |
| Hummel, M; Leithäuser, F; Möller, P; Ritz, O; Stein, H; Ushmorov, A; Wirth, T | 1 |
| Leithäuser, F; Möller, P; Popov, SW; Sakk, O; Ushmorov, A; Weinhaüsel, A; Wirth, T | 1 |
15 other study(ies) available for azacitidine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hodgkin Disease; Humans; Retinoic Acid 4-Hydroxylase; RNA Interference; Signal Transduction; Tretinoin | 2013 |
Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Immunoblotting; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Purines; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine | 2014 |
DLI after haploidentical BMT with post-transplant CY.
Topics: Adolescent; Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Leukemia; Living Donors; Lymphocyte Transfusion; Middle Aged; Recurrence; Survival Rate; Time Factors | 2015 |
Epigenetic regulation of microRNA expression in Hodgkin lymphoma.
Topics: Azacitidine; Cell Line, Tumor; Cluster Analysis; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Lymph Nodes; MicroRNAs; Promoter Regions, Genetic; Reproducibility of Results; Transcriptome | 2015 |
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Azacitidine; Cell Cycle Checkpoints; DNA Methylation; Hodgkin Disease; Humans; Nivolumab; Remission Induction; Salvage Therapy | 2016 |
Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine.
Topics: Antibodies, Monoclonal; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Myositis; Neoplasms, Second Primary; Nivolumab; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2017 |
Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Oligonucleotide Array Sequence Analysis; Oncogenes; Signal Transduction; Small Molecule Libraries | 2017 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Hodgkin Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Epitopes; Feasibility Studies; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Molecular Targeted Therapy; Neoplasm Proteins; Recurrence; T-Lymphocytes; Up-Regulation | 2011 |
MAGE: the spell is broken.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Neoplasm Proteins; T-Lymphocytes | 2011 |
Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines.
Topics: Acetylation; Apoptosis; Azacitidine; Butyrates; Cell Line, Tumor; Checkpoint Kinase 2; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histones; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma; Methylation; Protein Serine-Threonine Kinases; RNA, Messenger | 2004 |
Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Octamer Transcription Factor-2; Promoter Regions, Genetic; Trans-Activators; Transcription Factors; Transcription, Genetic | 2004 |
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.
Topics: Azacitidine; B-Lymphocytes; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Promoter Regions, Genetic; Reed-Sternberg Cells; Transcription Factors | 2006 |